6 active not recruiting. 6 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Active not recruiting 6 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Small Cell Lung Cancer: new trials by email Literature Review of Small Cell Lung Cancer trials Research Report on Small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms ETOPOSIDE - Usual, ETOPOSIDE - Study - Small Cell Lung Cancer | Phase 2 / Phase 3 | Active not recruiting | Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair | 600 | 2025-07-16 | 2026-08-27 |
| A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302) YL201, topotecan hydrochloride for injection - Small Cell Lung Cancer | Phase 3 | Active not recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | 438 | 2024-12-17 | 2026-09-15 |
| A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) BL-B01D1, Topotecan - Small Cell Lung Cancer | Phase 3 | Active not recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 722 | 2024-08-07 | 2026-04-17 |
| Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Tarlatamab, Placebo - Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 3 | Active not recruiting | Amgen | 404 | 2024-02-20 | 2026-04-29 |
| Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline) - Small Cell Lung Cancer | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 672 | 2020-12-08 | 2026-09-24 |
| Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy Durvalumab, Tremelimumab, Placebo - Small Cell Lung Cancer | Phase 3 | Active not recruiting | AstraZeneca | 730 | 2018-09-27 | 2025-11-21 |
Small Cell Lung Carcinoma (6) · Carcinoma (1) · Lung Neoplasms (1) · Neoplasms (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1)
Bronchial Neoplasms (6) · Carcinoma, Bronchogenic (6) · Lung Diseases (6) · Neoplasms by Site (6) · Respiratory Tract Diseases (6) · Respiratory Tract Neoplasms (6) · Thoracic Neoplasms (6) · Lung Neoplasms (5) · Neoplasms (5) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1)
Topotecan (2) · AMG 757 (1) · BID protein, human (1) · Drug Therapy (1) · Etoposide (1) · Injections (1) · Platinum (1) · Sodium Chloride (1) · durvalumab (1) · olaparib (1) · pembrolizumab (1) · tremelimumab (1)
Amgen (1) · AstraZeneca (1) · Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair (1) · MediLink Therapeutics (Suzhou) Co., Ltd. (1) · Merck Sharp & Dohme LLC (1) · Sichuan Baili Pharmaceutical Co., Ltd. (1)
China (5) · United States (4) · Belgium (3) · Italy (3) · Japan (3) · South Korea (3) · Spain (3) · Turkey (Türkiye) (3) · United Kingdom (3) · Argentina (2) · Australia (2) · Bulgaria (2) · Canada (2) · France (2) · Germany (2)
Haiyi Jiang, M.D. (1) · Li Zhang (1)
PMID 31948903, PMID 35613997, PMID 39268857, PMID 40976711, PMID 41921748, PMID 42497381, PMID 42734213, PMID 42806195
2023 (2), 2018 (1), 2019 (1)